# US 2018/0021416 A1 · Treatment of diseases related to hyperactivity of the complement system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021416 A1
- Document ID: US20180021416A1
- Status: Published application
- Kind: A1
- Application number: 15/720,933
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2009-03-13
- Assignees: Cambridge Enterprise Limited
- Applicants: Cambridge Enterprise Limited
- Inventors: Peter Lachmann
- Web page: https://patentgrep.com/patent/US20180021416A1

## CPC

- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/48: acting on peptide bonds (3.4)
- C12N 9/48: acting on peptide bonds (3.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 74

A method of lowering the amount of C3b activity in a subject, the method comprising:
increasing the level of C3b-inactivating activity and/or iC3b degrading activity in the subject;
wherein the level of C3b-inactivating activity and/or iC3b degrading activity in the subject is increased to a level that exceeds a normal level of C3b-inactivating activity and/or iC3b degrading activity in the subject.

### Claim 75 (depends on 74)

The method according to claim 74, further comprising not increasing the level of Factor H in the subject.

### Claim 76 (depends on 74)

The method according to claim 74, wherein increasing the level of C3b-inactivating activity and/or iC3b degrading activity in the subject comprises increasing the level of Factor I in the subject.

### Claim 77 (depends on 76)

The method according to claim 76, wherein the Factor I has at least 90% amino acid identity with native Factor I; and
wherein the Factor I retains C3b-inactivating activity and/or iC3b degrading activity.

### Claim 78 (depends on 74)

The method according to claim 74, wherein the level of C3b-inactivating activity and/or iC3b degrading activity is increased by at least 10% above the normal level.

### Claim 79 (depends on 74)

The method according to claim 74, wherein the level of C3b-inactivating activity and/or iC3b degrading activity is increased by no more than 50% above the normal level.

### Claim 80 (depends on 74)

The method according to claim 74, wherein the subject has a normal level of C3b-inactivating activity and/or iC3b degrading activity prior to increasing the level of C3b-inactivating activity and/or iC3b degrading activity in the subject.

### Claim 81 (depends on 74)

The method according to claim 74, wherein the subject is human.

### Claim 82 (depends on 74)

The method according to claim 74, wherein the subject suffers from Age-related Macular Degeneration or atypical hemolytic uremic syndrome.

### Claim 83 (depends on 74)

The method according to claim 74, wherein the level of C3b-inactivating activity and/or iC3b degrading activity in the plasma of the subject is increased to a level that exceeds a normal level of C3b-inactivating activity and/or iC3b degrading activity in the plasma of the subject.

### Claim 84 (depends on 83)

The method according to claim 83, wherein the normal level is in the range of 30-40 μg/ml Factor I in the plasma of the subject.

### Claim 85 (depends on 74)

The method according to claim 74, wherein the level of C3b-inactivating activity and/or iC3b degrading activity in an eye of the subject is increased to a level that exceeds a normal level of C3b-inactivating activity and/or iC3b degrading activity in an eye of the subject.
